Larry Puls is an Oncology physician affiliated with Prisma Health. OpenAlex indexes 42 publications with 1,285 citations (h-index 18); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
900 W Faris Rd
Greenville, SC 296054255
Telephone
864-404-2010Registry record last updated 31 Jan 2018.
Clinical trials
- Safety and Efficacy Study of Glufosfamide in Ovarian Cancer
Sponsor: Eleison Pharmaceuticals LLC.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20254 payments
- Daiichi Sankyo Inc.Program year20251 payment
- ABBVIE INC.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
51.9%Nonsteroidal Anti-inflammatory Drug27.7%Celecoxib100%Part D≥84 patientsKinase inhibitor13.2%Lenvima100%Part D≥13 patients+ 2 more classes in this area
Nervous system
25.5%Gabapentinoids25.5%Pregabalin100%Part D≥79 patientsBlood & clotting
11.6%Factor Xa inhibitor11.6%Eliquis100%Part D≥21 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Differential Expression of KRAS and SIRT1 in Ovarian Cancers with and Without Endometriosis
Reproductive Sciences
2020 - Mutational analysis of selected high-grade malignancies in a premenopausal gynecologic cancer population: a potential for targeted therapies?
Applied cancer research/Applied Cancer Research
2018
Similar KOLs
Other experts from the same institution or the same specialty.
Gopi Dandamudi, MD
Prisma Health
Ezequiel Gleichgerrcht, MD, PhD
Prisma Health
Anthony Gregg, MD
Prisma Health
Fredy Revilla, MD
Prisma Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”